

Publications

Reports and guidelines:

- WPRO Meeting Report: WHO 2013 consolidated guidelines on the use of antiretrovirals for the treatment and prevention of HIV in Asia and the Pacific held 16-18 September 2013 in Beijing, China
- Meeting report Regional Core Group Meeting for the Validation of the Elimination of Parents-to-Child Transmission of HIV and Syphilis in Asia and the Pacific 10 November 2014 Bangkok Thailand
- Progress Review and Road Map: Elimination of parent-to-child transmission of HIV and Syphilis in Asia and the Pacific in 2015 and beyond © UNICEF East Asia and Pacific Regional Office, August 2016 <http://www.wpro.who.int/hiv/documents/topics/pmtct/20160909-eptct-progress-report.pdf>
- Meeting report for the 10th Asia-Pacific United Nations Task Force for the Prevention of Parent-to-Child Transmission of HIV and Syphilis. UNICEF East Asia and Pacific Regional Office, August 2016
- National Guidelines on Diagnosis and Antiretroviral Treatment of HIV Infection in Infants, Children and Adolescents in Cambodia 2016(4th edition) <http://www.nchads.org/index.php?id=22>
- Meeting reports for the Fifth Hepatitis B Immunization Expert Resource Panel Consultation in Manila, and the Expert Consultation on Triple Elimination of Mother-to-Child Transmission of HIV, Hepatitis B and Syphilis in the Western Pacific in Manila, Philippines, 15-17 February 2017 and 20-21 February 2017 respectively

Selected Peer-reviewed publications:

1. Meyers T, Moultrie H, Naidoo K, Cotton M, Eley B, Sherman G. Challenges to pediatric HIV care and treatment in South Africa. *J Infect Dis* 2007;196: S474-81.
Impact factor 12.13 Citations 85
 2. Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. *J Acquir Immune Defic Syndr*. 2008 Apr 15;47(5):566-9.
Impact factor 8.55 Citations 75
 3. Ren Y, Nuttall JJ, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. *J Acquir Immune Defic Syndr*. 2009 Apr 15;50(5):439-43.
Impact factor 8.55 Citations 41
 4. Smith K, Kuhn L, Coovadia A, Meyers T, Hu CC, Reitz C, Barry G, Strehlau R, Sherman G, Abrams EJ. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. *AIDS*. 2009 Jun 1;23(9):1097-107.
Impact factor 4.91 citations 69
-

5. Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, Malan E, Marais B, Strehlau R, Ledwaba J, Hammer SM, Morris L, Kuhn L. Persistent Minority K103N Mutations among Women Exposed to Single-Dose Nevirapine and Virologic Response to Non-nucleoside Reverse-Transcriptase Inhibitor-Based Therapy. 1: Clin Infect Dis. 2009 Jan 9.

Impact factor 8.195 Citations 70

6. Yotebieng M, Vanrie A, Moultrie H, Meyers T. Six-month gain in weight, height, and CD4 predict subsequent antiretroviral treatment responses in HIV-infected South African children. AIDS 2010 Jan 2;24(1):139-46.

Impact factor 6.438 Citations 16

7. Reitz C, Coovadia A, Ko S, Meyers T, Strehlau R, Sherman G, Kuhn L, Abrams EJ. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis. 2010 Apr 15;201(8):1121-31. PubMed PMID: 20214476; PubMed Central PMCID: PMC2946637.

Impact factor 6.288 Citations 36

8. Viljoen M, Gous H, Kruger HS, Riddick A, Meyers TM, Rheeders M. Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children. AIDS Res Hum Retroviruses. 2010 Jun;26(6):613-9.

Impact factor 2.082 Citations 8

9. Meyers TM, Ndung'u T. Case records of the Massachusetts General Hospital. Case 18-2010. A 7-year-old boy with elevated HIV RNA levels despite antiretroviral medications. N Engl J Med. 2010 Jun 17;362(24):2305-12. Erratum in: N Engl J Med. 2010 Sep 30;363(14):1383-4. PubMed PMID: 20554986.

Impact factor 53.484. Citations 1

10. Yotebieng M, Van Rie A, Moultrie H, Cole SR, Adimora A, Behets F, Meyers T. Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. AIDS. 2010 Jun 1;24(9):1341-9. PubMed PMID: 20559039.

Impact factor 6.438 Citations: 30

11. Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, Sherman G, Hunt G, Hu CC, Tsai WY, Morris L, Kuhn L. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA. 2010 Sep 8;304(10):1082-90. PubMed PMID: 20823434.

Impact factor 30.011 Citations 59

12. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, Bwakura-Dangarembizi M, Chi BH, Musoke P, Kamthunzi P, Schimana W, Purdue L, Eshleman SH, Abrams EJ, Millar L, Petzold E, Mofenson LM, Jean-Philippe P, Violari A. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010 Oct 14;363(16):1510-20. PubMed PMID: 20942667.

Impact factor 53.298(2011) Citations: 144

13. Coetzer M, Nedellec R, Cilliers T, Meyers T, Morris L, Mosier DE. Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C. *J Acquir Immune Defic Syndr*. 2011 Jan 1;56(1):9-15.
Impact factor 4.425. Citations 23
 14. McIlleron H, Ren Y, Nuttall J, Fairlie L, Rabie H, Cotton M, Eley B, Meyers T, Smith PJ, Merry C, Maartens G. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. *Antivir Ther*. 2011;16(3):417-21. **Impact factor 3.161 citations 30**
 15. Dramowski A, Coovadia A, Meyers T and Goga A. Identifying missed opportunities for early intervention among HIV-infected paediatric admissions at Chris Hani Baragwanath hospital, Soweto, South Africa *Southern African Journal of HIV Medicine* - Vol 12, No 4 (2011) 16-23 **Citations: 5**
 16. Moorthy A, Kuhn L, Coovadia A, Meyers T, Strehlau R, Sherman G, Tsai WY, Chen YH, Abrams EJ, Persaud D. Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. *Clin Infect Dis*. 2011 Feb;52(4):514-21. Epub 2011 Jan 22. PubMed PMID: 21258105; PubMed Central PMCID: PMC3060899.
Impact factor 9.154 Citations 18
 17. Taylor BS, Hunt G, Abrams EJ, Coovadia A, Meyers T, Sherman G, Strehlau R, Morris L, Kuhn L. Rapid Development of Antiretroviral Drug Resistance Mutations in HIV-Infected Children Less Than Two Years of Age Initiating Protease Inhibitor-Based Therapy in South Africa. *AIDS Res Hum Retroviruses*. 2011 Mar 23. [Epub ahead of print] PubMed PMID: 21345162.
Impact factor 2.246 Citations: 24
 18. Frohoff C, Moodley M, Fairlie L, Coovadia A, Moultrie H, Kuhn L, Meyers T. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. *PLoS One*. 2011 Feb 23;6(2): e17273. PubMed PMID: 21383838; PubMed Central PMCID: PMC3044164.
Impact Factor 4.092 Citations: 21
 19. Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, Morris L, Kuhn L. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. *AIDS*. 2011 Jul 31;25(12):1461-9. PubMed PMID: 21633285. I
Impact Factor 6.557 Citations 24
 20. Meyers TM, Yotebieng M, Kuhn L, Moultrie H. Antiretroviral Therapy Responses Among Children Attending a Large Public Clinic in Soweto, South Africa. *Pediatr Infect Dis J*. 2011 Jul 15. [Epub ahead of print] PubMed PMID: 21734620.
Impact factor 3.135 Citations: 25
 21. Eley BS, Meyers T. Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents. *Paediatr Drugs*. 2011 Oct 1;13(5):303-16.
Impact factor 1.721 Citations 5
-

22. Viljoen M, Karlsson MO, Meyers TM, Gous H, Dandara C, Rheeders M. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children. *Eur J Clin Pharmacol*. 2012 Apr;68(4):339-47.
Impact factor 2.754 Citations 9
23. Lowick S, Sawry S, Meyers T. Neurodevelopmental delay among HIV-infected preschool children receiving antiretroviral therapy and healthy preschool children in Soweto, South Africa. *Psychol Health Med*. 2012;17(5):599-610.
Impact factor 1.532 Citations: 13
24. Meyers T, Dramowski A, Schneider H, Gardiner N, Kuhn L, Moore D. Changes in paediatric HIV-related hospital admissions and mortality in Soweto, South Africa 1996-2011: light at the end of the tunnel? *J Acquir Immune Defic Syndr*. 2012 Apr 6. [Epub ahead of print] PubMed PMID: 22487588.
Impact factor 4.394 Citations: 6
25. Kuhn L, Coovadia A, Strehlau R, Martens L, Hu CC, Meyers T, Sherman G, Hunt G, Persaud D, Morris L, Tsai WY, Abrams EJ. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. *Lancet Infect Dis*. 2012 Jul;12(7):521-30.
Impact Factor 18.279 Citations: 25
26. Palmer M, Chersich M, Moultrie H, Kuhn L, Fairlie L, Meyers T. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in Soweto, South Africa. *AIDS*. 2012 Nov 19. [Epub ahead of print] 2013 Mar 13;27(5):781-5.
Impact factor 6.557 Citations: 7
27. Kruger HS, Balk LJ, Viljoen M, Meyers TM. Positive association between dietary iron intake and iron status in HIV-infected children in Johannesburg, South Africa. *Nutr Res*. 2013 Jan;33(1):50-8. doi: 10.1016/j.nutres.2012.11.008. Epub 2012 Dec 20. PubMed PMID: 23351410
Impact factor 2.742
28. Nuttal, JJ, Meyers T and Eley B. Clinical utility of raltegravir for the treatment of HIV infection in children and adolescents. *Pediatric Health, Medicine and Therapeutics* 2013;4 75–87 Dovepress open access
29. Fairlie L, Muchiri E, Beylis CN, Meyers T, Moultrie H. Microbiological investigation for tuberculosis among HIV-infected children in Soweto, South Africa. *Int J Tuberc Lung Dis*. 2014 Jun;18(6):676-81.
Impact factor 2.76
30. Yotebieng M, Meyers T, Behets F, Davies MA, Keiser O, Ngonyani KZ, Lyamuya RE, Kariminia A, Hansudewechakul R, Leroy V, Koumakpai S, Newman J, Van Rie A. Age-specific and sex-specific weight gain norms to monitor antiretroviral therapy in children in low-income and middle-income countries. *AIDS*. 2015 Jan 2;29(1):101-9.
Impact factor 6.557
31. Meyers T, Sawry S, Wong, JY, Moultrie H, Pinillos, F, Fairlie L, van Zyl G Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa. *Pediatr Infect Dis J*. 2015 Feb;34(2):175-9.
-

Impact factor 3.135

